Acetylated K676 TGFBIp as a severity diagnostic blood biomarker for SARS-CoV-2 pneumonia
Hee Ho Park, Hong Nam Kim, Hyelim Kim, Youngbum Yoo, Hyosoo Shin, Eun Young Choi, Jong‐Sup Bae, Wonhwa Lee
Abstract
= 113), especially in patients in the intensive care unit (ICU) compared to non-ICU patients. Patients' blood samples showed increased cytokines and lymphopenia, which are exemplary indicators of SARS-CoV-2 pneumonia. Treatment with TGFBIp neutralizing antibodies suppressed the cytokine storm. The increased level of TGFBIp K676Ac in ICU patients suggests the promise of this protein as a reliable severity diagnostic biomarker for severe SARS-CoV-2 disease.
Topics & Concepts
BiomarkerMedicinePneumoniaCytokine stormOutbreakIntensive care unitDiseaseImmunologyCoronavirusViral pneumoniaSeverity of illnessInternal medicineCoronavirus disease 2019 (COVID-19)Intensive care medicineVirologyInfectious disease (medical specialty)BiologyBiochemistryCOVID-19 Clinical Research StudiesImmune cells in cancerHematological disorders and diagnostics